Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

Cited In for PubMed (Select 16797805)

1.

Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunity.

Ascough S, Ingram RJ, Chu KK, Reynolds CJ, Musson JA, Doganay M, Metan G, Ozkul Y, Baillie L, Sriskandan S, Moore SJ, Gallagher TB, Dyson H, Williamson ED, Robinson JH, Maillere B, Boyton RJ, Altmann DM.

PLoS Pathog. 2014 May 1;10(5):e1004085. doi: 10.1371/journal.ppat.1004085. eCollection 2014 May.

2.

Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant.

Feinen B, Petrovsky N, Verma A, Merkel TJ.

Clin Vaccine Immunol. 2014 Apr;21(4):580-6. doi: 10.1128/CVI.00019-14. Epub 2014 Feb 19.

3.

Intramuscular delivery of adenovirus serotype 5 vector expressing humanized protective antigen induces rapid protection against anthrax that may bypass intranasally originated preexisting adenovirus immunity.

Wu S, Zhang Z, Yu R, Zhang J, Liu Y, Song X, Yi S, Liu J, Chen J, Yin Y, Xu J, Hou L, Chen W.

Clin Vaccine Immunol. 2014 Feb;21(2):156-64. doi: 10.1128/CVI.00560-13. Epub 2013 Dec 4.

4.

In vitro and in vivo activities of recombinant anthrax protective antigen co-expressed with thioredoxin in Escherichia coli.

Ma Y, Yu YZ, Zhu YF, Xu Q, Sun ZW.

Hum Vaccin Immunother. 2013 Nov;9(11):2371-7. Epub 2013 Jul 23.

5.

Human leukocyte antigens and cellular immune responses to anthrax vaccine adsorbed.

Ovsyannikova IG, Pankratz VS, Vierkant RA, Pajewski NM, Quinn CP, Kaslow RA, Jacobson RM, Poland GA.

Infect Immun. 2013 Jul;81(7):2584-91. doi: 10.1128/IAI.00269-13. Epub 2013 May 6.

6.

Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.

Dumas EK, Nguyen ML, Cox PM, Rodgers H, Peterson JL, James JA, Farris AD.

Vaccine. 2013 Apr 3;31(14):1856-63. doi: 10.1016/j.vaccine.2013.01.040. Epub 2013 Feb 13.

7.

A plant-produced protective antigen vaccine confers protection in rabbits against a lethal aerosolized challenge with Bacillus anthracis Ames spores.

Chichester JA, Manceva SD, Rhee A, Coffin MV, Musiychuk K, Mett V, Shamloul M, Norikane J, Streatfield SJ, Yusibov V.

Hum Vaccin Immunother. 2013 Mar;9(3):544-52. Epub 2013 Jan 16.

8.

Anthrax lethal toxin and the induction of CD4 T cell immunity.

Ascough S, Ingram RJ, Altmann DM.

Toxins (Basel). 2012 Oct;4(10):878-99. doi: 10.3390/toxins4100878. Epub 2012 Oct 19. Review.

9.

Identification of novel and cross-species seroreactive proteins from Bacillus anthracis using a ligation-independent cloning-based, SOS-inducible expression system.

McWilliams BD, Palzkill T, Weinstock GM, Petrosino JF.

Microb Pathog. 2012 Nov-Dec;53(5-6):250-8. doi: 10.1016/j.micpath.2012.08.006. Epub 2012 Sep 10.

10.

Stable dry powder formulation for nasal delivery of anthrax vaccine.

Wang SH, Kirwan SM, Abraham SN, Staats HF, Hickey AJ.

J Pharm Sci. 2012 Jan;101(1):31-47. doi: 10.1002/jps.22742. Epub 2011 Sep 8.

11.

Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.

Brown BK, Cox J, Gillis A, VanCott TC, Marovich M, Milazzo M, Antonille TS, Wieczorek L, McKee KT Jr, Metcalfe K, Mallory RM, Birx D, Polonis VR, Robb ML.

PLoS One. 2010 Nov 5;5(11):e13849. doi: 10.1371/journal.pone.0013849.

12.

DNA vaccines for targeting bacterial infections.

Ingolotti M, Kawalekar O, Shedlock DJ, Muthumani K, Weiner DB.

Expert Rev Vaccines. 2010 Jul;9(7):747-63. doi: 10.1586/erv.10.57. Review.

13.

Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways.

Langley WA, Bradley KC, Li ZN, Smith ME, Schnell MJ, Steinhauer DA.

J Virol. 2010 Aug;84(16):8300-7. doi: 10.1128/JVI.00183-10. Epub 2010 May 26.

14.

Comparison of three anthrax toxin neutralization assays.

Ngundi MM, Meade BD, Lin TL, Tang WJ, Burns DL.

Clin Vaccine Immunol. 2010 Jun;17(6):895-903. doi: 10.1128/CVI.00513-09. Epub 2010 Apr 7.

15.

Technical transformation of biodefense vaccines.

Lu S, Wang S.

Vaccine. 2009 Nov 5;27 Suppl 4:D8-D15. doi: 10.1016/j.vaccine.2009.08.055. Review.

16.

Anthrax vaccination strategies.

Cybulski RJ Jr, Sanz P, O'Brien AD.

Mol Aspects Med. 2009 Dec;30(6):490-502. doi: 10.1016/j.mam.2009.08.006. Epub 2009 Sep 1. Review.

17.

Analysis of the Fc gamma receptor-dependent component of neutralization measured by anthrax toxin neutralization assays.

Verma A, Ngundi MM, Meade BD, De Pascalis R, Elkins KL, Burns DL.

Clin Vaccine Immunol. 2009 Oct;16(10):1405-12. doi: 10.1128/CVI.00194-09. Epub 2009 Aug 5.

18.

Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults.

Keitel WA, Treanor JJ, El Sahly HM, Evans TG, Kopper S, Whitlow V, Selinsky C, Kaslow DC, Rolland A, Smith LR, Lalor PA.

Hum Vaccin. 2009 Aug;5(8):536-44. Epub 2009 Aug 14.

19.

Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax.

Skoble J, Beaber JW, Gao Y, Lovchik JA, Sower LE, Liu W, Luckett W, Peterson JW, Calendar R, Portnoy DA, Lyons CR, Dubensky TW Jr.

Infect Immun. 2009 Apr;77(4):1649-63. doi: 10.1128/IAI.00530-08. Epub 2009 Jan 21.

20.

Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine.

Galen JE, Chinchilla M, Pasetti MF, Wang JY, Zhao L, Arciniega-Martinez I, Silverman DJ, Levine MM.

J Infect Dis. 2009 Feb 1;199(3):326-35. doi: 10.1086/596066.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk